Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 11, 2024Advances in TherapyOpen Access

Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2

View Full Paper
Ask AI
Bookmark
Share

Authors

CHClaire HarrisonNational Health ServiceAlessandro M. VannucchiAlessandro M. VannucchiUniversité Paris-SudCRChristian RécherCentre National de la Recherche Scientifique

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Harrison et al. (2024) studied this question.

synapsesocial.com/papers/68e609bdb6db64358759cc10https://doi.org/10.1007/s12325-024-02928-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis2023 · 81 citations
  2. 2Evaluation of Hemoglobin Cutoff Levels to Define Anemia Among Healthy Individuals2021 · 119 citations
  3. 3SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis2017 · 388 citations